Abbassian, H, Esmaeili, P, Tahamtan, M, Aghaei, I, Vaziri, Z, Sheibani, V,Whalley, BJ and Shabani, M (2016) Cannabinoid receptor agonism suppresses tremor, cognition disturbances and anxiety-like behaviors in a rat model of essential tremor. Physiology and Behavior 164, 314–320.
Adamczyk, P, Gołda, A, McCreary, AC, Filip, M and Przegaliński, E (2008) Activation of endocannabinoid transmission induces antidepressant-like effects in rats. Journal of Physiology and Pharmacology 59, 217–228.
Agrawal, A, Nurnberger, JI and Lynskey, MT (2011) Cannabis involvement in individuals with bipolar disorder. Psychiatry Research 185, 459–461.
Alpak, G, Copoglu, S, Geyik, E, Unal, A, Igci, M, Igci, YZ, Bozgeyik, I, Bulbul, F and Savas, HA (2014) CNR1 gene polymorphisms on bipolar disorder patients. Klinik Psikofarmakoloji Bulteni 24, S274–S275.
Andre, CM, Hausman, J-F and Guerriero, G (2016) Cannabis sativa: the plant of the thousand and one molecules. Frontiers in Plant Science 7, 19.
Arjmand, S, Behzadi, M, Stephens, GJ, Ezzatabadipour, S, Seifaddini, R,Arjmand, S and Shabani, M (2017) A brain on a roller coaster: can the Dopamine Reward System Act as a protagonist to subdue the ups and downs of bipolar disorder? Neuroscientist 24, 423–439.
Arjmand, S, Vaziri, Z, Behzadi, M, Abbassian, H, Stephens, GJ and Shabani, M (2015) Cannabinoids and tremor induced by motor-related disorders: friend or foe? Neurotherapeutics 12, 778–787.
Ashok, AH, Marques, TR, Jauhar, S, Nour, MM, Goodwin, GM, Young, AH and Howes, OD (2017) The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Molecular Psychiatry 22, 666–679.
Ashton, CH, Moore, PB, Gallagher, P and Young, AH (2005) Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. Journal of Psychopharmacology 19, 293–300.
Ashton, JC and Glass, M (2007) The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Current Neuropharmacology 5, 73–80.
Atakan, Z (2012) Cannabis, a complex plant: different compounds and different effects on individuals. Therapeutic Advances in Psychopharmacology 2, 241–254.
Atwood, BK and Mackie, K (2010) CB2: a cannabinoid receptor with an identity crisis. British Journal of Pharmacology 160, 467–479.
Baethge, C, Baldessarini, RJ, Khalsa, HMK, Hennen, J, Salvatore, P and Tohen, M (2005) Substance abuse in first-episode bipolar I disorder: indications for early intervention. American Journal of Psychiatry 162, 1008–1010.
Baethge, C, Hennen, J, Khalsa, H-MK, Salvatore, P, Tohen, M and Baldessarini, RJ (2008) Sequencing of substance use and affective morbidity in 166 first-episode bipolar I disorder patients. Bipolar Disorders 10, 738–741.
Bally, N, Zullino, D and Aubry, JM (2014) Cannabis use and first manic episode. Journal of Affective Disorders 165, 103–108.
Berk, M, Kapczinski, F, Andreazza, AC, Dean, OM, Giorlando, F, Maes, M, Yücel, M, Gama, CS, Dodd, S, Dean, B, Magalhães, PV, Amminger, P, McGorry, P and Malhi, GS (2011) Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience & Biobehavioral Reviews 35, 804–817.
Bertolín-Guillén, JM, López-Arquero, FJ, Martínez-Franco, L (2008) Cannabis-induced mania? Journal of Substance Use 13, 139–141.
Beyer, CE, Dwyer, JM, Piesla, MJ, Platt, BJ, Shen, R, Rahman, Z,Chan, K, Manners, MT, Samad, TA, Kennedy, JD, Bingham, B and Whiteside, GT (2010) Depression-like phenotype following chronic CB1 receptor antagonism. Neurobiology of Disease 39, 148–155.
Bishop, LC, Bisset, AD and Benson, JI (1987) Mania and indomethacin. Journal of Clinical Psychopharmacology 7, 203–204.
Bitter, SM, Adler, CM, Eliassen, JC, Weber, WA, Welge, JA, Burciaga, J,Shear, PK, Strakowski, SM, DelBello, MP (2014) Neurofunctional changes in adolescent cannabis users with and without bipolar disorder. Addiction 109, 1901–1909.
Boufidou, F, Nikolaou, C, Alevizos, B, Liappas, IA and Christodoulou, GN (2004) Cytokine production in bipolar affective disorder patients under lithium treatment. Journal of Affective Disorders 82, 309–313.
Brietzke, E, Kauer-Sant’Anna, M, Teixeira, AL and Kapczinski, F (2009a) Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behavior, and Immunity 23, 1079–1082.
Brietzke, E, Stertz, L, Fernandes, BS, Kauer-Sant’Anna, M, Mascarenhas, M, Escosteguy Vargas, A,Chies, JA and Kapczinski, F (2009b) Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. Journal of Affective Disorders 116, 214–217.
Burokas, A, Martín-García, E, Gutiérrez-Cuesta, J, Rojas, S, Herance, JR, Gispert, JD,Serra, MÁ and Maldonado, R (2014) Relationships between serotonergic and cannabinoid system in depressive-like behavior: a PET study with [11 C]-DASB. Journal of Neurochemistry 130, 126–135.
Carvalho, AF and Van Bockstaele, EJ (2012) Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry 38, 59–67.
Cassidy, F, Ahearn, EP and Carroll, BJ (2001) Substance abuse in bipolar disorder. Bipolar Disorders 3, 181–188.
Chang, MCJ, Contreras, MA, Rosenberger, TA, Rintala, JJO, Bell, JM and Rapoport, SI (2001) Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. Journal of Neurochemistry 77, 796–803.
Choi, K, Le, T, McGuire, J, Xing, G, Zhang, L, Li, H, Parker, CC, Johnson, LR and Ursano, RJ (2012) Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear. Journal of Psychiatric Research 46, 882–889.
Cunha, ÂB, Andreazza, AC, Gomes, FA, Frey, BN, Da Silveira, LE, Gonçalves, CA and Kapczinski, F (2008) Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience 258, 300–304.
De Berardis, D, Conti, CM, Campanella, D, Carano, A, Scali, M, Valchera, A, Serroni, N, Pizzorno, AM, D’Albenzio, A, Fulcheri, M, Gambi, F, La Rovere, R, Cotellessa, C, Salerno, RM and Ferro, FM (2008) Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder. International Journal of Immunopathology and Pharmacology 21, 319–324.
De Hert, M, Wampers, M, Jendricko, T, Franic, T, Vidovic, D, De Vriendt, N,Sweers, K, Peuskens, J and van Winkel, R (2011) Effects of cannabis use on age at onset in schizophrenia and bipolar disorder. Schizophrenia Research 126, 270–276.
Dickerson, F, Stallings, C, Origoni, A, Boronow, J and Yolken, R (2007) Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31, 952–955.
Ehrhart, J, Obregon, D, Mori, T, Hou, H, Sun, N, Bai, Y, Klein, T, Fernandez, F, Tan, J and Shytle, RD (2005) Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. Journal of Neuroinflammation 2, 29.
Ekdahl, CT (2012) Microglial activation – tuning and pruning adult neurogenesis. Frontiers in Pharmacology 3, 41.
Esteban, S and García-Sevilla, JA (2012) Effects induced by cannabinoids on monoaminergic systems in the brain and their implications for psychiatric disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry 38, 78–87.
Fagiolini, A, Forgione, R, Maccari, M, Cuomo, A, Morana, B, Dell’Osso, MC, Pellegrini, F and Rossi, A (2013) Prevalence, chronicity, burden and borders of bipolar disorder. Journal of Affective Disorders 148, 161–169.
Feingold, D, Weiser, M, Rehm, J and Lev-Ran, S (2015) The association between cannabis use and mood disorders: a longitudinal study. Journal of Affective Disorders 172, 211–218.
Gibbs, M, Winsper, C, Marwaha, S, Gilbert, E, Broome, M and Singh, SP (2014) Cannabis use and mania symptoms: a systematic review and meta-analysis. Journal of Affective Disorders 171, 39–47.
Giraldo, J (2010) How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue. Drug Discovery Today 15, 411–415.
Gobbi, G, Bambico, FR, Mangieri, R, Bortolato, M, Campolongo, P, Solinas, M,Cassano, T, Morgese, MG, Debonnel, G, Duranti, A, Tontini, A, Tarzia, G, Mor, M, Trezza, V, Goldberg, SR, Cuomo, V and Piomelli, D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proceedings of the National Academy of Sciences 102, 18620–18625.
Goldstein, BI, Kemp, DE, Soczynska, JK and McIntyre, RS (2009) Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder. Journal of Clinical Psychiatry 70, 1078–1090.
Gonzalez-Pinto, A, Reed, C, Novick, D, Bertsch, J and Haro, JM (2010) Assessment of medication adherence in a cohort of patients with bipolar disorder. Pharmacopsychiatry 43, 263–270.
Griebel, G, Stemmelin, J and Scatton, B (2005) Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biological Psychiatry 57, 261–267.
Grinspoon, L and Bakalar, JB (1998) The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. Journal of Psychoactive Drugs 30, 171–177.
Gruber, AJ, Pope, HGJ and Brown, ME (1996) Do patients use marijuana as an antidepressant? Depression 4, 77–80.
Haghani, M, Shabani, M, Javan, M, Motamedi, F and Janahmadi, M (2012) CB1 cannabinoid receptor activation rescues amyloid β-induced alterations in behaviour and intrinsic electrophysiological properties of rat hippocampal CA1 pyramidal neurones. Cellular Physiology and Biochemistry 29, 391–406.
Hamdani, N, Tamouza, R and Leboyer, M (2012) Immuno-inflammatory markers of bipolar disorder: a review of evidence. Frontiers in Bioscience (Elite Edition) 4, 2170–2182.
Healey, C, Peters, S, Kinderman, P, McCracken, C and Morriss, R (2009) Reasons for substance use in dual diagnosis bipolar disorder and substance use disorders: a qualitative study. Journal of Affective Disorders 113, 118–126.
Henquet, C, Krabbendam, L, de Graaf, R, ten Have, M and van Os, J (2006) Cannabis use and expression of mania in the general population. Journal of Affective Disorders 95, 103–110.
Hill, MN and Gorzalka, BB (2005) Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. European Neuropsychopharmacology 15, 593–599.
Hillard, CJ, Weinlander, KM and Stuhr, KL (2012) Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 204, 207–229.
Hou, L, Heilbronner, U, Degenhardt, F, Adli, M, Akiyama, K, Akula, N,Ardau, R, Arias, B, Backlund, L, Banzato, CEM, Benabarre, A, Bengesser, S, Bhattacharjee, AK, Biernacka, JM, Birner, A, Brichant-Petitjean, C, Bui, ET, Cervantes, P, Chen, GB, Chen, HC, Chillotti, C, Cichon, S, Clark, SR, Colom, F, Cousins, DA, Cruceanu, C, Czerski, PM, Dantas, CR, Dayer, A, Étain, B, Falkai, P, Forstner, AJ, Frisén, L, Fullerton, JM, Gard, S, Garnham, JS, Goes, FS, Grof, P, Gruber, O, Hashimoto, R, Hauser, J, Herms, S, Hoffmann, P, Hofmann, A, Jamain, S, Jiménez, E, Kahn, JP, Kassem, L, Kittel-Schneider, S, Kliwicki, S, König, B, Kusumi, I, Lackner, N, Laje, G, Landén, M, Lavebratt, C, Leboyer, M, Leckband, SG, Jaramillo, CAL, MacQueen, G, Manchia, M, Martinsson, L, Mattheisen, M, McCarthy, MJ, McElroy, SL, Mitjans, M, Mondimore, FM, Monteleone, P, Nievergelt, CM, Nöthen, MM, Ösby, U, Ozaki, N, Perlis, RH, Pfennig, A, Reich-Erkelenz, D, Rouleau, GA, Schofield, PR, Schubert, KO, Schweizer, BW, Seemüller, F, Severino, G, Shekhtman, T, Shilling, PD, Shimoda, K, Simhandl, C, Slaney, CM, Smoller, JW, Squassina, A, Stamm, T, Stopkova, P, Tighe, SK, Tortorella, A, Turecki, G, Volkert, J, Witt, S, Wright, A, Young, LT, Zandi, PP, Potash, JB, DePaulo, JR, Bauer, M, Reininghaus, EZ, Novák, T, Aubry, JM, Maj, M, Baune, BT, Mitchell, PB, Vieta, E, Frye, MA, Rybakowski, JK, Kuo, PH, Kato, T, Grigoroiu-Serbanescu, M, Reif, A, Del Zompo, M, Bellivier, F, Schalling, M, Wray, NR, Kelsoe, JR, Alda, M, Rietschel, M, McMahon, FJ and Schulze, TG (2016) Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet 387, 1085–1093.
Huang, T-L and Lin, F-C (2007) High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31, 370–372.
Jones, NA, Glyn, SE, Akiyama, S, Hill, TDM, Hill, AJ, Weston, SE,Burnett, MD, Yamasaki, Y, Stephens, GJ, Whalley, BJ and Williams, CM (2012) Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 21, 344–352.
Kato, T (2007) Molecular genetics of bipolar disorder and depression. Psychiatry and Clinical Neurosciences 61, 3–19.
Khan, MA and Akella, S (2009) Cannabis-induced bipolar disorder with psychotic features: a case report. Psychiatry (Edgmont) 6, 44–48.
Kim, H-W, Rapoport, SI and Rao, JS (2011) Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Molecular Psychiatry 16, 419–428.
Kim, YK, Jung, HG, Myint, AM, Kim, H and Park, SH (2007) Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. Journal of Affective Disorders 104, 91–95.
Koethe, D, Llenos, IC, Dulay, JR, Hoyer, C, Torrey, EF, Leweke, FM and Weis, S (2007) Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. Journal of Neural Transmission 114, 1055–1063.
Kruk-Slomka, M, Michalak, A and Biala, G (2015) Antidepressant-like effects of the cannabinoid receptor ligands in the forced swimming test in mice: mechanism of action and possible interactions with cholinergic system. Behavioural Brain Research 284, 24–36.
Lagerberg, TV, Kvitland, LR, Aminoff, SR, Aas, M, Ringen, PA, Andreassen, OA and Melle, I (2014) Indications of a dose-response relationship between cannabis use and age at onset in bipolar disorder. Psychiatry Research 215, 101–104.
Leboyer, M, Soreca, I, Scott, J, Frye, M, Henry, C, Tamouza, R and Kupfer, DJ (2012) Can bipolar disorder be viewed as a multi-system inflammatory disease? Journal of Affective Disorders 141, 1–10.
Leclerc, E, Mansur, RB and Brietzke, E (2013) Determinants of adherence to treatment in bipolar disorder: a comprehensive review. Journal of Affective Disorders 149, 247–252.
Leite, RTP, De Oliveira Nogueira, S, Do Nascimento, JPR, De Lima, LS, Da Nóbrega, TB, Da Silva Virgínio, M,Moreno, LM, Sampaio, BH, de Matos, E and Souza, FG (2015) The use of cannabis as a predictor of early onset of bipolar disorder and suicide attempts. Neural Plasticity 2015, 434127.
Lev-Ran, S, Le Foll, B, McKenzie, K, George, TP and Rehm, J (2013) Bipolar disorder and co-occurring cannabis use disorders: characteristics, co-morbidities and clinical correlates. Psychiatry Research 209, 459–465.
Leweke, FM and Koethe, D (2008) Cannabis and psychiatric disorders: it is not only addiction. Addiction Biology 13, 264–275.
Lu, H-C and Mackie, K (2016) An introduction to the endogenous cannabinoid system. Biological Psychiatry 79, 516–525.
Mahajan, NS, Mahajan, R and Mittal, R (2012) NSAID induced hypomania in stable bipolar disorder. Indian Journal of Psychiatry 54, 293.
Malfitano, AM, Basu, S, Maresz, K and Bifulco, M (2014) What we know and do not know about the cannabinoid receptor 2 (CB2). Seminars in Immunology 26, 369–379.
Malhi, GS, Porter, R, Irwin, L, Hamilton, A, Morris, G, Bassett, D, Baune, BT, Boyce, P, Hopwood, MJ, Mulder, R, Parker, G, Mannie, Z, Outhred, T, Das, P and Singh, AB (2018) Defining a mood stabiliser: novel framework for research and clinical practice. BJPsych Open 4, 278–281.
Mariangela Corbo, EC (2015) Cannabis and methylphenidate-induced manic symptoms. Journal of Clinical Toxicology 5, 1–5.
Merikangas, KR, Herrell, R, Swendsen, J, Rössler, W, Ajdacic-Gross, V and Angst, J (2008) Specificity of bipolar spectrum conditions in the comorbidity of mood and substance use disorders: results from the Zurich cohort study. Archives of General Psychiatry 65, 47–52.
Micale, V, Di Marzo, V, Sulcova, A, Wotjak, CT, Drago, F (2013) Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacology & Therapeutics 138, 18–37.
Minocci, D, Massei, J, Martino, A, Milianti, M, Piz, L, Di Bello, D,Sbrana, A, Martinotti, E, Rossi, AM and Nieri, P (2011) Genetic association between bipolar disorder and 524A>C (Leu133Ile) polymorphism of CNR2 gene, encoding for CB2 cannabinoid receptor. Journal of Affective Disorders 134, 427–430.
Monteleone, P, Bifulco, M, Maina, G, Tortorella, A, Gazzerro, P, Proto, MC,Di Filippo, C, Monteleone, F, Canestrelli, B, Buonerba, G, Bogetto, F and Maj, M (2010) Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacology Research 61, 400–404.
Moreira, FA and Crippa, JAS (2009) The psychiatric side-effects of rimonabant. Revista Brasileira de Psiquiatria 31, 145–153.
O’Brien, SM, Scully, P, Scott, LV and Dinan, TG (2006) Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. Journal of Affective Disorders 90, 263–267.
Öngür, D, Lin, L and Cohen, BM (2009) Clinical characteristics influencing age at onset in psychotic disorders. Comprehensive Psychiatry 50, 13–19.
Ortiz-Domínguez, A, Hernández, ME, Berlanga, C, Gutiérrez-Mora, D, Moreno, J, Heinze, G, and Pavón, L (2007) Immune variations in bipolar disorder: phasic differences. Bipolar Disorders 9, 596–602.
Oswald, P, Souery, D, Kasper, S, Lecrubier, Y, Montgomery, S, Wyckaert, S,Zohar, J and Mendlewicz, J (2007) Current issues in bipolar disorder: a critical review. European Neuropsychopharmacology 17, 687–695.
Pearce, DD, Mitsouras, K and Irizarry, KJ (2014) Discriminating the effects of Cannabis sativa and Cannabis indica: a web survey of medical cannabis users. Journal of Alternative and Complementary Medicine 20, 787–791.
Pisanu, C, Congiu, D, Costa, M, Sestu, M, Chillotti, C, Ardau, R,Deiana, V, Manchia, M, Squassina, A and Del Zompo, M (2013) No association of endocannabinoid genes with bipolar disorder or lithium response in a Sardinian sample. Psychiatry Research 210, 887–890.
Rao, JS and Rapoport, SI (2009) Mood-stabilizers target the brain arachidonic acid cascade. Current Molecular Pharmacol 2, 207–214.
Rapoport, SI (2014) Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade. ACS Chemical Neuroscience 5, 459–467.
Roche, M and Finn, DP (2010) Brain CB2 receptors: implications for neuropsychiatric disorders. Pharmaceuticals 3, 2517–2533.
Rybakowski, JK (2013) Genetic influences on response to mood stabilizers in bipolar disorder. CNS Drugs 27, 165–173.
Shorter, E (2009) The history of lithium therapy. Bipolar Disorders 11, 4–9.
Sotsky, SM and Tossell, JW (1984) Tolmetin induction of mania. Psychosomatics 25, 626–628.
Sportiche, S, Geoffroy, PA, Brichant-Petitjean, C, Gard, S, Khan, J-P, Azorin, J-M,Henry, C, Leboyer, M, Etain, B, Scott, J and Bellivier, F (2016) Clinical factors associated with lithium response in bipolar disorders. Australian & New Zealand Journal of Psychiatry 51, 524–530.
Steiner, MA, Marsicano, G, Nestler, EJ, Holsboer, F, Lutz, B and Wotjak, CT (2008) Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 33, 54–67.
Stertz, L, Magalhães, PVS and Kapczinski, F (2013) Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Current Opinion in Psychiatry 26, 19–26.
Strakowski, SM, DelBello, MP, Fleck, DE, Adler, CM, Anthenelli, RM, Keck, PE,Arnold, LM and Amicone, J (2007) Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Archives of General Psychiatry 64, 57.
Stratton, HJ, Allen, DL, Wu, J and Shafer, MS (2013) Modulation of the endogenous cannabinoid system as a therapeutic target in the treatment of mental health disorders. Biochemical Pharmacology Open Access S, 1–8.
Sublette, ME, Russ, MJ and Smith, GS (2004) Evidence for a role of the arachidonic acid cascade in affective disorders: a review. Bipolar Disorders 6, 95–105.
Tijssen, MJA, Van Os, J, Wittchen, HU, Lieb, R, Beesdo, K, Wichers, M (2010) Risk factors predicting onset and persistence of subthreshold expression of bipolar psychopathology among youth from the community. Acta Psychiatrica Scandinavica 122, 255–266.
Turcotte, C, Blanchet, MR, Laviolette, M and Flamand, N (2016) The CB2 receptor and its role as a regulator of inflammation. Cellular and Molecular Life Sciences 73, 4449–4470.
Turcotte, C, Chouinard, F, Lefebvre, JS and Flamand, N (2015) Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. Journal of Leukocyte Biology 97, 1049–1070.
Tyler, E, Jones, S, Black, N, Carter, L-A and Barrowclough, C (2015) The relationship between bipolar disorder and cannabis use in daily life: an experience sampling study. PLoS One 10, e0118916.
Valverde, O and Torrens, M (2012) CB1 receptor-deficient mice as a model for depression. Neuroscience 204, 193–206.
Van Der Stelt, M and Di Marzo, V (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. European Journal of Pharmacology 480, 133–150.
Van Laar, M, Van Dorsselaer, S, Monshouwer, K, De Graaf, R (2007) Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction 102, 1251–1260.
van Rossum, I, Boomsma, M, Tenback, D, Reed, C and van Os, J (2009) Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis. The Journal of Nervous and Mental Disease 197, 35–40.
Vinod, KY and Hungund, BL (2005) Endocannabinoid lipids and mediated system: implications for alcoholism and neuropsychiatric disorders. Life Sciences 77, 1569–1583.
Vinod, KY and Hungund, BL (2006) Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders. Expert Opinion on Therapeutic Targets 10, 203–210.
Viscomi, MT, Oddi, S, Latini, L, Pasquariello, N, Florenzano, F, Bernardi, G, Molinari, M and Maccarrone, M (2009) Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. Journal of Neuroscience 29, 4564–4570.
Wadee, AA, Kuschke, RH, Wood, LA, Berk, M, Ichim, L and Maes, M (2002) Serological observations in patients suffering from acute manic episodes. Human Psychopharmacology 17, 175–179.
Walker, JM and Huang, SM (2002) Cannabinoid analgesia. Pharmacology & Therapeutics 95, 127–135.
Ward, SJ and Raffa, RB (2011) Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies. Obesity 19, 1325–1334.
Wei, D and Piomelli, D (2015) Cannabinoid-based drugs: potential applications in addiction and other mental disorders. Focus (Madison) 13, 307–316.
Weitz, TM and Town, T (2012) Microglia in Alzheimer’s disease: it’s all about context. International Journal of Alzheimer’s Disease 2012, 1–11.
Yamaguchi, T, Shoyama, Y, Watanabe, S and Yamamoto, T (2001) Behavioral suppression induced by cannabinoids is due to activation of the arachidonic acid cascade in rats. Brain Research 889, 149–154.
Yang, H, Zhang, J, Andreasson, K and Chen, C (2008) COX-2 oxidative metabolism of endocannabinoids augments hippocampal synaptic plasticity. Molecular and Cellular Neuroscience 37, 682–695.
Zuardi, A, Crippa, J, Dursun, S, Morais, S, Vilela, J, Sanches, R and Hallak, J (2010) Cannabidiol was ineffective for manic episode of bipolar affective disorder. Journal of Psychopharmacology 24, 135–137.
Zuardi, AW (2006) History of cannabis as a medicine: a review. Revista Brasileira de Psiquiatria 28, 153–157.